The #AIEye: IBM (NYSE: $IBM) Launches #AI-Powered BTI and Accenture (NYSE: $ACN) Doubles Size of DC Digital Studio
AI in Life Sciences to Grow at CAGR of 21.1% from 2019-2024
Point Roberts WA, Vancouver BC – May 14, 2019 – Investorideas.com (www.investorideas.com), a global investor news source covering Artificial Intelligence (AI) brings you today’s edition of The AI Eye- watching stock news, deal tracker and advancements in artificial intelligence.
Listen to today’s podcast:
Read this in full at https://www.investorideas.com/news/2019/artificial-intelligence/05141AIEye-IBM-ACN.asp
Today’s Column- The AI Eye- Watching stock news, deal tracker and advancements in artificial intelligence
Stocks discussed: (NYSE:IBM) (NYSE:ACN)
IBM (NYSE:IBM) today launched its Business Transactional Intelligence (BTI). According to the press release, BTI is “an AI-powered solution that offers anomaly detection and visualization capabilities for mitigating supply chain disruptions and accelerating data-driven decision making”. Connie Rekau, EDI [electronic data interchange] Manager, The Master Lock Company, explains:
"With IBM Business Transaction Intelligence, we can dig deeper into our EDI data to identify patterns that wouldn't otherwise be obvious. As well as building a scorecard to track our performance against internal service-level level agreements [SLAs] with the business, we have set up reports that highlight trading partners with higher-than-average error rates."
Accenture (NYSE:ACN) has announced a doubling of the size of its Accenture Federal Digital Studio in Washington, D.C., making the facility over 20,000 square feet and increasing the size its the team as well. The Studio helps clients create digital solutions through the use of AI and analytics. John Goodman, CEO of Accenture Federal Services (AFS), said:
“Our newly expanded Studio will help government leaders gain new perspectives, embrace new technologies faster, adopt successful approaches from the private sector, and activate them for the good of our society and our nation.”
AI in Life Sciences to Grow at CAGR of 21.1% from 2019-2024
A report recently published on Industry Research finds that the AI in Life Sciences Market, currently valued at $902.1 million USD, is projected to exhibit a compound annual growth rate (CAGR) of 21.1 percent from 2019 to 2024. An excerpt from the report description reads:
As AI operates on large sets of data, the availability of such data becomes a key factor for establishing a suitable environment for the growth of AI-based solutions. With innovations in mobile technology and sensors, even the present day's wearables like smartwatches and fitness trackers, have enough computing power to generate and process vast amounts of data.
In fact, according to the recent estimates of Consumer Technology Association, a prominent standard and trade organization for the consumer electronics industry based in the United States, health and fitness trackers accounted for more than 47% of the wearables devices sold in 2017. This scenario coupled with several medical devices used in healthcare sector generates huge sets of data that could make use of AI to derive useful results.
AI is increasingly becoming popular in drug discovery, personalized medicine, biotechnology, and clinical trials. With increasing healthcare spending in almost all parts of the world, the pharmaceutical industry has been involved in extreme R&D activities in the past few years.
Sam Mowers, Investorideas.com
For a list of artificial intelligence stocks on Investorideas.com visit here or become an Investor Ideas member
About Investorideas.com - News that Inspires Big Investing Ideas Investorideas.com is a recognized news source publishing third party news and press releases plus we create original financial content. Learn about investing in stocks and sector trends from Investorideas.com with our news alerts , articles , podcasts and videos talking about cannabis, crypto, technology including AI and IoT , mining ,sports biotech, water, renewable energy and more . Investorideas.com original branded content includes the daily Crypto Corner and Podcast, Play by Play sports and stock news column, Investor Ideas #Potcasts #Cannabis News and Stocks on the Move podcast and column, Cleantech and Climate Change Podcast and the AI Eye Podcast and column covering developments in AI.
The Investorideas.com podcasts are also available on iTunes, Spotify, Tunein, Stitcher, Spreaker.com, iHeartRadio and Google Play Music.
Visit the Podcast page at Investorideas.com:
Disclaimer/Disclosure: Investorideas.com is a digital publisher of third party sourced news, articles and equity research as well as creates original content, including video, interviews and articles. Original content created by investorideas is protected by copyright laws other than syndication rights. Our site does not make recommendations for purchases or sale of stocks, services or products. Nothing on our sites should be construed as an offer or solicitation to buy or sell products or securities. All investing involves risk and possible losses. This site is currently compensated for news publication and distribution, social media and marketing, content creation and more. Disclosure is posted for each compensated news release, content published /created if required but otherwise the news was not compensated for and was published for the sole interest of our readers and followers. Contact management and IR of each company directly regarding specific questions.
More disclaimer info: https://www.investorideas.com/About/Disclaimer.asp Learn more about publishing your news release and our other news services on the Investorideas.com newswire https://www.investorideas.com/News-Upload/ and tickertagstocknews.com
Global investors must adhere to regulations of each country. Please read Investorideas.com privacy policy: https://www.investorideas.com/About/Private_Policy.asp
The AI Eye- Watching stock news, deal tracker and advancements in artificial intelligence is an original content brand of Investorideas.com
Contact Investorideas.com
800 665 0411
No comments:
Post a Comment